Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 22;29(8):5955-5962.
doi: 10.3390/curroncol29080470.

Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Yasmine Kadri  1 , Michelle Phan  2 , Nadia Bambace  1   3 , Léa Bernard  1   3 , Sandra Cohen  1   3 , Jean-Sébastien Delisle  1   3 , Thomas Kiss  1   3 , Sylvie Lachance  1   3 , Denis-Claude Roy  1   3 , Guy Sauvageau  1   3 , Olivier Veilleux  1   3 , Jean Roy  1   3 , Imran Ahmad  1   3
Affiliations

Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Yasmine Kadri et al. Curr Oncol. .

Abstract

The purpose of this retrospective study was to study the correlation between donor age (DA) and non-relapse mortality (NRM) and relapse incidence (RI) among patients treated with allogeneic hematopoietic cell transplantation (aHCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in a single Canadian center. Data from 125 consecutive patients transplanted with a matched related or unrelated donor between 2015 and 2020 were analyzed using multivariable models. After a median follow-up of 2.8 years, the cumulative incidences of NRM and relapse were 19% and 35% at 5 years. Despite being independently associated with NRM and relapse-free survival (RFS), DA was not associated with RI. The independent determinants of NRM in addition to DA were patient age and hematopoietic cell transplantation comorbidity index (HCT-CI), independently of donor kinship. The effect of DA on NRM was found to be significantly increased over the age of 50 years. DA was not associated with incidence of acute graft-versus-host disease (aGVHD) but showed an association with the occurrence of chronic GVHD (cGVHD). In conclusion, younger donors should be favored to limit NRM and increase RFS in HLA-matched aHCT. The etiological mechanisms behind the association of DA with higher NRM remain to be elucidated.

Keywords: acute myeloid leukemia; allogenic hematopoietic cell transplantation; donor age; graft-versus-host disease; myelodysplastic syndrome; non-relapse mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Overall and relapse-free survival. (b) Cumulative incidences of relapse and non-relapse mortality.
Figure 2
Figure 2
Cumulative incidence of NRM among patients with donor aged (a) <50 years versus ≥50 years; (b) <60 years versus ≥60 years; (c) adjusted hazard ratios (HR) of various donor ages for the association with NRM (reference is <30 y).
See this image and copyright information in PMC

References

    1. D’Souza A., Fretham C., Lee S.J., Arora M., Brunner J., Chhabra S., Devine S., Eapen M., Hamadani M., Hari P., et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol. Blood Marrow Transpl. 2020;26:e177–e182. doi: 10.1016/j.bbmt.2020.04.013. - DOI - PMC - PubMed
    1. McDonald G.B., Sandmaier B.M., Mielcarek M., Sorror M., Pergam S.A., Cheng G.S., Hingorani S., Boeckh M., Flowers M.D., Lee S.J., et al. Survival, Nonrelapse Mortality, and Relapse-Related Mortality after Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 versus 2013–2017 Cohorts. Ann. Intern. Med. 2020;172:229–239. doi: 10.7326/M19-2936. - DOI - PMC - PubMed
    1. Passweg J.R., Baldomero H., Chabannon C., Basak G.W., de la Cámara R., Corbacioglu S., Dolstra H., Duarte R., Glass B., Greco R., et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: Monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651–1664. doi: 10.1038/s41409-021-01227-8. - DOI - PMC - PubMed
    1. Penack O., Peczynski C., Mohty M., Yakoub-Agha I., Styczynski J., Montoto S., Duarte R.F., Kröger N., Schoemans H., Koenecke C., et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283–6290. doi: 10.1182/bloodadvances.2020003418. - DOI - PMC - PubMed
    1. Lin R.J., Artz A.S. Allogeneic hematopoietic cell transplantation for older patients. Hemat. Am. Soc. Hematol. Educ. Program. 2021;2021:254–263. doi: 10.1182/hematology.2021000257. - DOI - PMC - PubMed

Publication types

MeSH terms